Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1396 studies found for:    "Multiple Sclerosis"
Show Display Options
Rank Status Study
21 Completed Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
Conditions: Relapsing Remitting Multiple Sclerosis (RRMS);   Secondary Progressive Multiple Sclerosis (SPMS)
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
22 Not yet recruiting A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Conditions: Secondary Progress Multiple Sclerosis;   Multiple Sclerosis
Interventions: Biological: NeuroVax;   Biological: IFA Placebo
23 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
24 Withdrawn Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Relapsing Forms of Multiple Sclerosis
Interventions: Drug: dimethyl fumarate;   Drug: Placebo
25 Temporarily not available Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
Conditions: Multiple Sclerosis;   Autoimmune Diseases;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Tetracycline - Statin - Antimycotic
26 Completed Bayer/Cognitive Assessments With Multiple Sclerosis Subjects
Conditions: Multiple Sclerosis, Relapsing-remitting;   Multiple Sclerosis, Secondary Progressive
Intervention:
27 Completed Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis, Secondary Progressive
Intervention: Biological: Tovaxin Autologous T Cell Vaccine
28 Recruiting Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Behavioral: Swank Diet;   Behavioral: Wahls Elimination Diet
29 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
30 Completed Safety of RG2077 in Patients With Multiple Sclerosis
Conditions: Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: RG2077 (CTLA4-IgG4m)
31 Active, not recruiting Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
32 Active, not recruiting Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases of the Nervous System;   Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Disease Progression;   Brain Atrophy
Interventions: Biological: Tcelna;   Biological: Placebo
33 Completed
Has Results
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
34 Completed
Has Results
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: natalizumab
35 Withdrawn Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
36 Active, not recruiting An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: dimethyl fumarate
37 Completed Treatment of Multiple Sclerosis Using Over the Counter Inosine
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Inosine
38 Completed A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
39 Active, not recruiting Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: BIIB019 (Daclizumab)
40 Recruiting Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
Conditions: Progressive Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Other: Neuropsychological assessment;   Other: Neurologic consultation;   Other: MRIs (with vasoreactivity testing)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years